Maureen Grady, PA
Physician Assistant · Battle Creek, MINPI 1306496872
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 747 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $4,496 and has fallen 97.1% since, to $130 in 2025. Among physician assistant clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 747 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Dexcom, Inc.$1K
- Sanofi-aventis U.S. LLC$682
- Amgen$653
- plus $6K from 44 others
What the payments were for
- Food & beverage$14,01299%
- Education$1281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$350
- FARXIGA$206
- CeQur Simplicity$194
- DEXCOM G6 TRANSMITTER$125
- Norditropin$125
- TEPEZZA$125
- t:slim X2 Insulin Pump with Control-IQ$124
- Kerendia$124
- DEXCOM G7 GSS (161)$112
- JARDIANCE$109
- RYBELSUS$101
How this compares
$14,140 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 187 | $292,233 |
| JardianceEmpagliflozin | 117 | $116,645 |
| MounjaroTirzepatide | 82 | $95,302 |
| TrulicityDulaglutide | 40 | $46,400 |
| EliquisApixaban | 40 | $46,127 |
| JanuviaSitagliptin Phosphate | 32 | $34,066 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $29,317 |
| FarxigaDapagliflozin Propanediol | 27 | $25,195 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $24,571 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $22,437 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $20,091 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $18,709 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $16,923 |
| LinzessLinaclotide | 16 | $15,545 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $13,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $3,203 | $309,770213 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,295 | $145,402137 claims |
| Boehringer IngelheimJardiance | $402 | $116,645117 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $46 | $53,74591 claims |
| PfizerEliquis | $298 | $46,12740 claims |
| MerckJanuvia | $457 | $34,06632 claims |
| AstraZenecaFarxiga | $1,196 | $25,19527 claims |
| AbbVieLinzess, Synthroid | $582 | $22,234114 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $682 | $9,41911 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $248 | $4,526384 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Battle Creek
- Kirstin TymkewBattle Creek$23K
- Julia SwaffordBattle Creek$16K
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.